—
C+
C+ The full Closelook — membership. Open the C+ overview

Ginkgo Bioworks Holdings (DNA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Ginkgo Bioworks Holdings

DNA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Ginkgo Bioworks builds a platform for engineering living cells, selling research services, lab tools and automation systems that other firms use to design organisms for medicines, crops, food and industrial materials. A separate arm, run through its Canopy and Horizon services, gathers genomic data and watches for biological threats for government and other clients. It is based in Boston, Massachusetts.
Where it sits in the stack
Ginkgo Bioworks does not sit in Rubin or Halo, our two AI build-out indices; it belongs instead to the healthcare sector, within the biotechnology industry group of our wider universe.
Who it is priced against
The diary's pack carries no peer group for Ginkgo; the market's own comparison is Twist Bioscience, another company selling synthetic biology and cell-engineering services.
Why Closelook tracks it
Ginkgo Bioworks holds a seat in the Russell 1000 but carries no Rubin or Halo seat and no Closelook score. It has been quoted once, in a Heresy piece on value investing that used the letters of its ticker as wordplay rather than as commentary on the company.
What the diary watches
The diary watches whether Ginkgo's biosecurity work grows enough to offset its research-services revenue, and whether the shares steady after their long slide against their moving averages.

Ginkgo Bioworks Holdings (DNA) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for DNA, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: initiation by Guggenheim, 2026-08-18

The Street on this name

Analyst actions and the latest print for DNA from the Closelook wires — third-party opinions on the record, not our readings.

  • Initiation Guggenheim — at Buy Initiated to Buy 2026-08-18

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Ginkgo Bioworks Holdings (DNA)?

Ginkgo Bioworks Holdings trades as DNA on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is DNA in a Closelook index?

Not currently — Ginkgo Bioworks Holdings is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does DNA trade against its moving averages?

Recovery attempt under the 200-day: Trades +2.5% vs the 50-day and -5% vs the 200-day average, 55.4% below the 52-week high and +46% off the 52-week low; a death cross printed 13 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Ginkgo Bioworks Holdings do?

Ginkgo Bioworks builds a platform for engineering living cells, selling research services, lab tools and automation systems that other firms use to design organisms for medicines, crops, food and industrial materials. A separate arm, run through its Canopy and Horizon services, gathers genomic data and watches for biological threats for government and other clients. It is based in Boston, Massachusetts. The diary's pack carries no peer group for Ginkgo; the market's own comparison is Twist Bioscience, another company selling synthetic biology and cell-engineering services.

Where does Ginkgo Bioworks Holdings sit in the AI build-out?

Ginkgo Bioworks does not sit in Rubin or Halo, our two AI build-out indices; it belongs instead to the healthcare sector, within the biotechnology industry group of our wider universe. Ginkgo Bioworks holds a seat in the Russell 1000 but carries no Rubin or Halo seat and no Closelook score. It has been quoted once, in a Heresy piece on value investing that used the letters of its ticker as wordplay rather than as commentary on the company.

What has Wall Street done on Ginkgo Bioworks Holdings recently?

The most recent analyst action on Ginkgo Bioworks Holdings on the Closelook wire is a initiation by Guggenheim on 2026-08-18 (at Buy). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

Where has Closelook written about Ginkgo Bioworks Holdings?

Ginkgo Bioworks Holdings appears in 1 Closelook piece, most recently Heresy: Value Investing — Tech-Free, a Flag of Inconvenience (2026-05-07). What Closelook said most recently: A portfolio of high-quality slow-growers, dutifully rebalanced, is a portfolio with built-in underperformance DNA . (Heresy, 2026-05-07). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for DNA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Heresy, “Value Investing — Tech-Free, a Flag of Inconvenience” (2026-05-07)

Mentioned on Closelook

Where DNA appears in the diary — 1 piece, newest first. Every link is our own writing.

Long reads

Related in the Closelook universe